Entasis Therapeutics to Present Data on ETX2514 and Entasis' Third Drug Candidate, ETX0282, at ASM Microbe 2017

May 22, 2017

WALTHAM, Mass. — May 22, 2017—Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced multiple presentations at the American Society of Microbiology (ASM) Microbe 2017 Conference, taking place June 1-5 in New Orleans, LA. Presentations will include data on Entasis' lead program, ETX2514, as well as an introduction to Entasis' third drug candidate, ETX0282.

The abstract titled "ETX1317, the Active Component of the Orally Available, Novel Diazabicyclooctenone ETX0282, Demonstrates Potential Utility against Multidrug Resistant *Enterobactericeae* Due to its Potent, Broad Spectrum Inhibition of Serine Beta-Lactamases," has been designated as an oral presentation and will be presented on Friday, June 2 at 3:30 PM.

The details of the presentations are as follows:

ETX2514 Presentations:

Poster #82: The Antibacterial Activity of Sulbactam and the Novel Beta-Lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem against Recent Clinical Isolates of *Acinetobacter baumannii* and *Pseudomonas aeruginosa*
Session: 036 – AAID01 – Antibacterial Resistance: Beta-lactamase and Carbapenemase Inhibitors
Date and Time: June 2, 2017 12:45 – 2:45 PM
Location: Exhibit Hall D

Poster #277: Reversibility of β-Lactamase Inhibition by the Broad-Spectrum Diazabicyclooctenone Serine β-Lactamase Inhibitor ETX2514
Session: 198 – AAID11 – New Antimicrobial Agents: New Beta-lactams and New Beta-lactamase Inhibitors
Date and Time: June 3, 2017 12:15 – 2:15 PM
Location: Exhibit Hall D

ETX0282 Presentations:

Oral Presentation Title: ETX1317, the Active Component of the Orally Available, Novel Diazabicyclooctenone ETX0282, Demonstrates Potential Utility against Multidrug Resistant *Enterobactericeae* Due to its Potent, Broad Spectrum Inhibition of Serine Beta-Lactamases
Session: 113 – Chemistry and Biological Attributes of Recent Beta-lactamase Inhibitors, Three Different Approaches to Enzyme Inhibitions
Date and Time: June 2, 2017 3:30 – 3:45 PM
Presentation Location: Room 225

Poster #278: ETX0282/Cefpodoxime Proxetil: A Novel, Oral Beta-Lactam/Beta-Lactamase Inhibitor Combination to Treat the Emerging Threat of Multidrug Resistant *Enterobacteriaceae*
Session: 198 – AAID11 – New Antimicrobial Agents: New Beta-lactams and New Beta-lactamase Inhibitors
Date and Time: June 3, 2017 12:15 – 2:15 PM
Location: Exhibit Hall D

Poster #279: The Antibacterial Activity of Cefpodoxime and the Novel Beta-Lactamase Inhibitor ETX1317 against Recent Clinical Isolates of Beta-Lactamase-Producing *Enterobacteriaceae* from Urinary Tract Infections
Session: 198 – AAID11 – New Antimicrobial Agents: New Beta-lactams and New Beta-lactamase Inhibitors
Date and Time: June 3, 2017 12:15 – 2:15 PM
Location: Exhibit Hall D

About ETX2514

ETX2514 is a potent and broad spectrum inhibitor of class A, C, and D beta-lactamases. ETX2514 restores the *in vitro* activity of multiple beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens. Entasis Therapeutics is developing ETX2514SUL, the combination of ETX2514 and sulbactam, for the treatment of severe *A. baumannii* infections. *A. baumannii* is a Gram-negative bacterium that causes severe infections which are associated with high mortality rates. *A. baumannii* infections are frequently multi-drug resistant and there is an urgent need to identify new safe and effective agents to treat affected patients. Sulbactam is a generic beta-lactam which has intrinsic activity against *A. baumannii* but suffers from widespread beta-lactamase-mediated resistance. In preclinical studies, ETX2514 restores sulbactam's antimicrobial activity against *A. baumannii*. ETX2514 is currently in Phase 1 clinical trials.

About ETX0282

ETX0282 is an orally available, broad spectrum inhibitor of class A and C beta-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime, an orally available cephalosporin approved for treating a variety of bacterial infections but lacking in efficacy due to beta-lactamase mediated resistance. In preclinical studies, ETX0282 restores cefpodoxime's antimicrobial activity against a variety of pathogens including *Enterobacteriaceae* resistant to fluoroquinolones, cephalosporins, and carbapenems. Entasis is initially developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime, for the treatment of infections caused by *Enterobacteriaceae*. ETX0282CPDP is *powered by CARB-X*.

About Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting *Acinetobacter baumannii*infections), ETX0282CPDP (targeting *Enterobacteriaceae* infections), and zoliflodacin (targeting *Neisseria gonorrhoeae*). www.entasistx.com

Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Media Contact
Kari Watson
MacDougall Biomedical Communications (781) 235-3060
kwatson@macbiocom.com